Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173405 · ClinicalTrials.gov registry record · Phase 1
Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain
A Phase 1 study of Trigger Point Pain, Myofascial and Myofascial Trigger Point Pain, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT02173405: Completed Phase 1 study of Trigger Point Pain, Myofascial and Myofascial Trigger Point Pain, sponsored by University Hospitals Cleveland Medical Center.
NCT02173405 is a Phase 1 study of Trigger Point Pain, Myofascial and Myofascial Trigger Point Pain that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173405, a Phase 1 study of Trigger Point Pain, Myofascial and Myofascial Trigger Point Pain, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study because is looking at woman with symptoms of chronic pelvic pain caused by short, tight, and tender pelvic floor muscles (Myofascial Pelvic Pain syndrome). The purpose of this study is to determine whether or not injections with onabotulinumtoxinA (Botox) improve symptoms of pain and tenderness. The drug being studied, Botox is FDA approved for other uses. However, Botox is not FDA approved for the use in myofascial pelvic pain (MPP). Therefore, Botox is considered experimental or research in this study.
Primary Outcome
a 30% reduction of pain and muscular spasm assessed by visual analog scale - VAS
Conditions Studied
Interventions
- DRUG Placebo
- DRUG OnabotulinumtoxinA
Study Locations (3)
Ohio
- University Case Medical Center - Cleveland
- University Hospitals Landerbrook Health Center, Urology - Mayfield Heights
- University Hospitals Westlake Health Center, Urology - Westlake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2016-09-01 |
| Phase | Phase 1 |
What the finished NCT02173405 record still lists
NCT02173405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Trigger Point Pain, Myofascial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02173405 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02173405 about?
NCT02173405 is a clinical study titled "Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain". This research study because is looking at woman with symptoms of chronic pelvic pain caused by short, tight, and tender pelvic floor muscles (Myofascial Pelvic Pain syndrome). The purpose of this study is to determine whether or not injections with onabotulinumtoxinA (Botox) improve symptoms of pain...
What is the current status of trial NCT02173405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-08-01. Estimated completion is 2016-09-01.
What conditions does trial NCT02173405 study?
This clinical trial studies the following conditions: Trigger Point Pain, Myofascial, Myofascial Trigger Point Pain, Myofascial Pain Syndromes.
What interventions are being tested in trial NCT02173405?
The interventions under investigation include: Placebo (DRUG), OnabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02173405?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02173405 being conducted?
This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trigger Point Pain, Myofascial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02173405's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI